Brief Description
The IGNAZ Study is looking at the safety and effectiveness of Felzartamab in adults 18 to 80 years old with IgA nephropathy. Researchers want to compare different doses of Felzartamab to see which one might be better than taking no medicine at all.
Estimated Enrollment
44
Estimated End Date
Last patient last visit January 2024
Trial is for people with
IgA nephropathy
Study Goal
IGNAZ seeks to investigate an innovative treatment option for IgA Nephropathy
What is involved for the patient?
During the study you would first be screened to make sure you are eligible for treatment. If so, you would be placed by chance in a ...
About the drug or intervention
Felzartamab belongs to a group of medicines called “monoclonal antibodies”, proteins designed to attach to specific cells or ...